Prostate International最新文献

{"title":"Dissemination of misleading and biased information about benign prostate hyperplasia on YouTube in the Republic of Korea","authors":"Min S. Song,&nbsp;Jeongwan Yoo,&nbsp;Hyun K. Jang,&nbsp;Byeong J. Jeon,&nbsp;Bum S. Tae,&nbsp;Jae H. Bae,&nbsp;Jae Y. Park","doi":"10.1016/j.prnil.2025.12.008","DOIUrl":"10.1016/j.prnil.2025.12.008","url":null,"abstract":"<div><h3>Background</h3><div>YouTube, a social media platform with over one billion users worldwide, has become a prominent source for health information among the public. Many individuals now turn to YouTube when seeking medical knowledge. This study aimed to evaluate the quality of health information presented in videos concerning benign prostatic hyperplasia (BPH) on YouTube.</div></div><div><h3>Methods</h3><div>We conducted a quality assessment of BPH-related content on YouTube in the Republic of Korea, analyzing the 100 most-viewed videos. The validated DISCERN instrument, a standardized tool for evaluating consumer health information, was used. DISCERN consists of 16 questions, each scored on a five-point scale (1 = poor, 2 = generally poor, 3 = moderate, 4 = good, 5 = excellent).</div></div><div><h3>Results</h3><div>The top 100 videos collectively accumulated 24.7 million views, with a median of 89,764 views per video and a median of 1,100 thumbs up per video. The mean DISCERN score for overall quality was 2.8, indicating a moderate level of information quality. Videos uploaded by urologists working in university hospitals and those posted by laypersons had a comparable number of views per video, while the latter received more thumbs up per video (2,752 vs 4,012). Fifty-two videos (52%) contained potentially misleading or commercially biased content, accumulating a total of 16.4 million views (3,15,456 views per video) and 5,182 thumbs up per video. A significant negative correlation was found between overall quality and views per month (r = −0.38, <em>P</em> &lt; 0.01), whereas no significant correlation was observed between scientific quality and the thumbs up/views ratio (r = 0.06, <em>P</em> = 0.58).</div></div><div><h3>Conclusions</h3><div>Low quality and layperson-generated YouTube videos on BPH gained more engagement than high-quality content. This highlights the paradoxical appeal of misleading and biased information and the need for stronger involvement of healthcare professionals to promote accurate and unbiased resources online.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 2","pages":"Pages 151-155"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The accuracy of transperineal template-guided mapping biopsy in patients with negative magnetic resonance imaging","authors":"Liang-yong Zhu,&nbsp;Cheng-hao Guo,&nbsp;Min Fang,&nbsp;Sheng-ming Lu,&nbsp;Yang Luan,&nbsp;Tian-bao Huang,&nbsp;Xiao Tan,&nbsp;Xue-fei Ding","doi":"10.1016/j.prnil.2026.02.001","DOIUrl":"10.1016/j.prnil.2026.02.001","url":null,"abstract":"<div><h3>Background</h3><div>The aim of this study was to assess the diagnostic accuracy and spatial localization capability of transperineal template-guided mapping biopsy (TTMB) in the detection of prostate cancer in patients with negative magnetic resonance imaging (MRI).</div></div><div><h3>Materials and methods</h3><div>A retrospective study was conducted to analyze the clinical data and follow-up outcomes of patients with negative MRI who underwent transperineal prostate biopsy at Northern Jiangsu People's Hospital, between January 2017 and August 2020. The patients were categorized into TTMB group and the systematic biopsy (SB) group according to the biopsy method. The biopsy positivity rate, detection rate of clinically significant prostate cancer (csPCa), pathological grade upgrading and downgrading following radical surgery, repeat biopsy rate, and positive rate of repeat biopsy were compared between the two patient groups. The diagnostic accuracy of TTMB in detecting and localizing prostate lesions was assessed using whole-mount radical prostatectomy specimens.</div></div><div><h3>Results</h3><div>A total of 398 patients were enrolled in the study, of whom 185 were in the TTMB group and 213 in the SB group. The TTMB group had significantly higher biopsy cores (53.5 vs. 18.1), biopsy-positive rate [28.1% (52/185) vs. 15.5% (33/213)], and csPCa rate [15.7% (29/185) vs. 8.9% (19/213)] than the SB group. In radical prostatectomy, compared with SB, the pathological downgrade of TTMB was higher (36.4% vs. 19.2%), and the pathological upgrade was lower (6.8% vs. 30.8%). The incidence of hematuria (37.8%), perineal hematoma (34%), and urinary retention (11.9%) in TTMB is significantly higher than in SB (<em>P</em> &lt; 0.05). The repeat biopsy rate (13.2%) and the csPCa detection rate (2.5%) in the TTMB group were both significantly lower than in the SB group (28.1% and 9.9). Whole-mount histopathological revealed 118 lesions, and 91.5% (108/118) lesions were detected by TTMB.</div></div><div><h3>Conclusions</h3><div>TTMB enhances biopsy accuracy and facilitates more precise detection and evaluation of tumor lesions patients with negative MRI.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 2","pages":"Pages 191-197"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic potentials of curcumin in prostate cancer: a comprehensive review of pathways and clinical prospects","authors":"Mohammad R. Fattahi,&nbsp;Fatemeh Shoja,&nbsp;Mohammad A. Mojaradi,&nbsp;Pariya Nazarinezhad,&nbsp;Hojat Dehghanbanadaki,&nbsp;Reza Arefnezhad,&nbsp;Fatemeh Rezaei-Tazangi,&nbsp;Habib Azimi","doi":"10.1016/j.prnil.2025.10.001","DOIUrl":"10.1016/j.prnil.2025.10.001","url":null,"abstract":"<div><div>Prostate cancer (PCa), which occurs mainly in men over the age of 65, is the most common cancer and the second-leading cause of cancer-related death in men. Depending on the condition, approaches like radical prostatectomy, chemotherapy, radiotherapy, and androgen-deprivation therapy may be used to treat the patient. However, none of these treatment methods are sufficient to treat PCa. Hence, significant efforts have been made to improve the quality of PCa treatment, and curcumin has demonstrated great potential as an effective treatment. Curcumin, a polyphenol found in the rhizome of turmeric, has attracted significant attention due to its effects on numerous cancer-related biological pathways. This review provides an overview of the efficacy of curcumin against prostate cancer and includes in vivo, in vitro, and human studies. The findings of this study suggest that curcumin can enhance PCa treatment by regulating several cellular signaling pathways, including androgen receptor (AR), activator protein 1 (AP-1), nuclear factor kappa-B (NF-κB), Bcl-2 family, Wnt/β-catenin, phosphoinositide 3-kinases/Akt (PI3K/Akt), and orchestrating the expression of oncogenic microRNAs and tumor suppressor microRNAs. Furthermore, research indicates that curcumin sensitizes cancer cells to radiotherapy and chemotherapy. In conclusion, curcumin shows great promise in improving prostate cancer treatment by targeting key cancer pathways and enhancing the effects of existing therapies. While its potential is clear, further clinical studies are needed to refine its use and ensure its effectiveness in real-world applications.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 2","pages":"Pages 105-115"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk stratification for repeat prostate biopsy: PI-RADS 3 lesions and the differential role of PSA density","authors":"Jungkeun Song,&nbsp;Jungwon Park,&nbsp;Hyungwoo Ahn,&nbsp;Sung Il Hwang,&nbsp;Hak Jong Lee,&nbsp;Younsoo Chung,&nbsp;Hyung Joon Kim,&nbsp;Hakmin Lee,&nbsp;Jong Jin Oh,&nbsp;Sangchul Lee,&nbsp;Seong Jin Jeong,&nbsp;Seok-Soo Byun,&nbsp;Sung Kyu Hong,&nbsp;Sang Hun Song","doi":"10.1016/j.prnil.2025.12.006","DOIUrl":"10.1016/j.prnil.2025.12.006","url":null,"abstract":"<div><h3>Purpose</h3><div>PI-RADS 3 lesions represent a diagnostic challenge in repeat prostate biopsy. We investigated whether PI-RADS 3 independently predicts negative biopsy outcomes and how PSA density (PSAD) modifies cancer detection across PI-RADS categories.</div></div><div><h3>Materials and methods</h3><div>We retrospectively analyzed 684 patients who underwent repeat MRI-guided prostate biopsy between 2015 and 2022. PI-RADS scores, clinicopathologic variables, biopsy Gleason Scores, and radical prostatectomy findings were assessed. Univariate and multivariate logistic regression identified predictors of positive biopsy. Subgroup analysis examined detection rates stratified by PI-RADS and PSAD.</div></div><div><h3>Results</h3><div>Overall, 238 patients (34.8 %) had positive biopsies. PI-RADS 3 was identified in 210 patients (30.7 %) and PI-RADS 4-5 in 274 (40.1 %). Cancer detection differed significantly: 19.0 % for PI-RADS 3 versus 51.8 % for PI-RADS 4-5 (<em>P</em> &lt; 0.001). Multivariate analysis confirmed PI-RADS 3 as an independent predictor of negative biopsy (OR 0.582, 95 % CI 0.364-0.929, <em>P</em> = 0.023), while PI-RADS 4-5 predicted positive biopsy (OR 2.438, <em>P</em> &lt; 0.001). PSAD strongly stratified risk in PI-RADS 4-5 lesions (33.8 % vs 62.4 %, <em>P</em> &lt; 0.001) but showed minimal effect in PI-RADS 3 lesions (16.2 % vs 20.7 %, <em>P</em> = 0.564).</div></div><div><h3>Conclusion</h3><div>PI-RADS 3 lesions independently predict negative biopsy in repeat MRI-guided prostate biopsy. PSAD demonstrates differential predictive utility across PI-RADS categories. Risk-stratified management incorporating imaging and clinical biomarkers may optimize decision-making while minimizing unnecessary procedures.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 2","pages":"Pages 138-143"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omitting biopsy in Prostate Imaging Reporting and Data System 3? The role of Stockholm3 and prostate-specific antigen density findings from a prospective Swiss non-referral cohort","authors":"Nicolas Arnold,&nbsp;Jonas Mudlagk,&nbsp;Odile Minder,&nbsp;Julian Cornelius,&nbsp;Carlo Di Bona,&nbsp;Beat Roth,&nbsp;Livio Mordasini,&nbsp;Nicola Giudici","doi":"10.1016/j.prnil.2026.04.002","DOIUrl":"10.1016/j.prnil.2026.04.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Prostate Imaging Reporting and Data System (PI-RADS) 3 (“equivocal”) prostate magnetic resonance imaging (MRI) lesions pose a diagnostic challenge, particularly in non-referral settings with variable MRI quality. We evaluated whether prostate-specific antigen density (PSAD) and the Stockholm3 blood test can aid biopsy decisions for men with PI-RADS 3 lesions in a prospective, non-referral Swiss cohort.</div></div><div><h3>Methods</h3><div>Retrospective analysis of a prospective registry at a non-referral urology practice in Switzerland. From 2023 to 2025, men with PSA &gt;1.5 ng/mL or suspicious digital rectal examination underwent Stockholm3 testing, MRI, and MRI-fusion plus systematic prostate biopsy. Clinically significant prostate cancer (csPCa) was defined as the International Society of Urological Pathology (ISUP) grade ≥2. Diagnostic accuracy and decision curve analysis compared Stockholm3 (≥13%, ≥15%, and ≥18%) and PSAD thresholds (0.10, 0.15, and 0.20 ng/mL/cc) within the PI-RADS 3 subgroup.</div></div><div><h3>Results</h3><div>Overall, 50 of 174 (29%) men had PI-RADS 3 lesions, 59 of 174 (34%) were diagnosed with csPCa. Among PI-RADS 3 lesions, csPCa prevalence was 14%. Outcome distributions shifted toward higher ISUP grades with increasing PSAD thresholds when compared to the baseline (≥0.15 ng/mL/cc: 44% ISUP≥2; <em>P</em> = 0.009), whereas Stockholm3 cut-offs showed no significant change for csPCa. As continuous measures, PSAD demonstrated superior discrimination (area under the receiver operating characteristic curve: 0.751; 95% confidence interval: 0.46–0.95) than Stockholm3 (area under the receiver operating characteristic curve: 0.595; 95% confidence interval: 0.30–0.88), confirming higher overall diagnostic accuracy within the PI-RADS 3 subgroup. Decision curve analysis demonstrated higher net benefit for PSAD-based approaches.</div></div><div><h3>Conclusion</h3><div>In non-referral practice, Stockholm3 did not reliably exclude csPCa among men with PI-RADS 3 lesions. PSAD-based triage, particularly at ≥0.15 ng/mL/cc, showed superior diagnostic utility and may support safe biopsy deferral in selected cases. Prospective validation in broader non-referral settings is warranted.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 2","pages":"Pages 198-203"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-6 secreted by tumor-associated macrophages promotes proliferation and migration through JAK2/STAT3 signaling pathway in human prostate cancer cells","authors":"Eunji Seok ,&nbsp;Dong Min Lee ,&nbsp;Hyunwon Yang ,&nbsp;Tag Keun Yoo","doi":"10.1016/j.prnil.2025.11.002","DOIUrl":"10.1016/j.prnil.2025.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Tumor-associated macrophages (TAMs) within the tumor microenvironment secrete cytokines that promote cancer progression, proliferation, and metastasis. In prostate cancer, disease progression is closely associated with cytokine activity, particularly interleukin-6 (IL-6), which activates STAT3 to regulate cellular proliferation. Therefore, this study investigated the mechanisms by which TAM-derived IL-6 interacts with prostate cancer cells to affect cancer cell proliferation and metastasis.</div></div><div><h3>Materials and methods</h3><div>THP-1 monocytes were differentiated into M0 macrophages using phorbol 12-myristate 13-acetate and subsequently co-cultured with conditioned medium (CM) from PC3 prostate cancer cells to induce TAM polarization. Cytokine secretion from TAMs was analyzed using qRT-PCR and cytokine arrays. PC3 cell proliferation, invasion, and migration were evaluated using MTT, Transwell invasion, and wound-healing assays, respectively.</div></div><div><h3>Results</h3><div>The expression of proliferation-related genes, including <em>TGF-α, TGF-β1, mTOR, FOS, CCND1,</em> and <em>PXN</em>, was assessed using qRT-PCR. The effect of IL-6 on JAK2/STAT3 signaling <em>was</em> examined using western blotting. CM from PC3 cells induced TAM polarization and significantly increased IL-6 expression in TAMs. TAMs enhanced the proliferation, invasion, and migration of PC3 cells, but these effects were suppressed by the STAT3 inhibitor WP1066 and IL-6 neutralizing antibodies. Furthermore, <em>TGF-α</em> and <em>FOS</em> expression was increased in PC3 cells co-cultured with TAMs, but this increase was reduced by WP1066 and IL-6 neutralizing antibody. IL-6 increased the activation of JAK2 and STAT3 proteins in PC3 cells, which was reduced by both treatments.</div></div><div><h3>Conclusions</h3><div>These findings underscore the role of TAMs in promoting prostate cancer progression through IL-6-mediated JAK2/STAT3 signaling, suggesting the potential of targeting this pathway as a therapeutic strategy for advanced prostate cancer.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 1","pages":"Pages 59-67"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147552197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence","authors":"Kieran Sandhu ,&nbsp;Sean Lim ,&nbsp;Nathan Lawrentschuk ,&nbsp;Declan G. Murphy ,&nbsp;Marlon Perera","doi":"10.1016/j.prnil.2025.09.006","DOIUrl":"10.1016/j.prnil.2025.09.006","url":null,"abstract":"<div><h3>Background</h3><div>Prostate-specific membrane antigen positron emission tomography (PSMA-PET) offers superior accuracy over conventional imaging for the primary staging of intermediate- to high-risk prostate cancer and in the biochemical recurrence (BCR) setting. In 2022, PSMA-PET became eligible for subsidy under Australia’s Medicare Benefits Schedule (MBS), reducing financial constraints and improving access for patients. This study presents the first national analysis of PSMA-PET uptake in Australia since MBS subsidization.</div></div><div><h3>Materials and methods</h3><div>This was a retrospective population-based analysis of PSMA-PET studies performed between July 2022 and March 2025 using MBS codes 61563 (primary staging) and 61564 (BCR). Data were stratified by year, state, age group, and setting and standardized per 100000 men using population data.</div></div><div><h3>Results</h3><div>A total of 90,412 PSMA-PET imaging studies were performed during the study period, with 60,995 for primary staging and 29,417 for BCR. There was a significant increase for primary staging with an average rise of 1.56 studies per 100000 men (<em>P</em> = 0.04; 95% confidence interval: 0.07–2.99). New South Wales recorded rapid and sustained growth, while Queensland maintained the highest per capita usage. Uptake for BCR rose modestly with similar geographic heterogeneity observed (<em>P</em> = 0.28; 95% confidence interval = 0.37–1.23).</div></div><div><h3>Conclusions</h3><div>Our findings demonstrate rapid and widespread uptake of PSMA-PET in Australia following MBS subsidization, especially in primary staging. Regional disparities in access persist, particularly in Western Australia and the Northern Territory. These findings highlight the impact of national health policy on imaging utilization to improve diagnostic staging, and detection of recurrence in prostate cancer, and emphasize the need to address geographic inequities in advancing diagnostic care.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 1","pages":"Pages 48-53"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147552198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of open versus robotic radical prostatectomy in renal transplant recipients and review of the literature","authors":"Thibaut Waeckel ,&nbsp;Arnaud Doerfler ,&nbsp;Clémence Bechade ,&nbsp;Xavier Tillou","doi":"10.1016/j.prnil.2025.11.004","DOIUrl":"10.1016/j.prnil.2025.11.004","url":null,"abstract":"<div><h3>Background</h3><div>Prostate cancer is the most common cancer among men, including renal transplant recipients (RTRs), who are becoming more numerous owing to improvements in transplant outcomes. Although radical prostatectomy (RP) remains a common curative procedure, RTRs present unique surgical challenges due to their altered pelvic anatomy and the need for immunosuppression. This study aimed to compare the perioperative, oncological, and functional outcomes of open radical prostatectomy (ORP) and robot-assisted radical prostatectomy (RARP) performed by two skilled surgeons on RTRs.</div></div><div><h3>Materials and methods</h3><div>Nineteen RTRs with localized prostate cancer who underwent RP between 1997 and 2023 were included in this retrospective, monocentric study. The patients were divided into two groups: RARP (<em>n</em> = 8) and ORP (<em>n</em> = 11). We analyzed preoperative data, perioperative metrics (blood loss and operative time), renal function, oncological outcomes (Prostate Specific Antigen (PSA)), and functional outcomes (erectile function and continence).</div></div><div><h3>Results</h3><div>Patients in The ORP group were older when they received their transplants. Significantly less blood loss was associated with RARP (median: 50 mL vs. 500 mL, <em>P</em> &lt; 0.001). The renal outcomes and operating times were similar between the groups. There were no significant differences in oncological outcomes, such as surgical margins and PSA control. Although there was little information on erectile function, continence was usually maintained in these patients.</div></div><div><h3>Conclusions</h3><div>RTRs can benefit from both ORP and RARP, with RARP showing advantages in terms of postoperative recovery and blood conservation. Robotic surgery may increase perioperative safety while maintaining oncological outcomes. To confirm these results and assess more recent surgical techniques developed specifically for RTRs, larger prospective studies are required.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 1","pages":"Pages 75-80"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147552134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-year outcomes of water vapor thermal therapy for benign prostatic hyperplasia","authors":"Ahmed Higazy ,&nbsp;Mohammed Zaza ,&nbsp;Mohammed Hassan Ali ,&nbsp;Mahmoud Elshahawy ,&nbsp;Tarek Salem ,&nbsp;Samir Azazy ,&nbsp;Muhammad Soliman","doi":"10.1016/j.prnil.2025.12.003","DOIUrl":"10.1016/j.prnil.2025.12.003","url":null,"abstract":"<div><h3>Background</h3><div>The Rezūm system offers a minimally invasive treatment option for alleviating lower urinary tract symptoms associated with benign prostatic hyperplasia. We report the 48-month outcomes from a single tertiary center.</div></div><div><h3>Materials and methods</h3><div>A retrospective study was conducted to review Rezūm therapy from 2021 to 2025 at our tertiary hospital. Maximum urinary flow rate, International Prostate Symptom Score, quality of life, post-void residual, prostate volume, and adverse events were actively monitored. Analyses were performed at baseline and at follow-up intervals of 3, 12, 24, 36, and 48 months.</div></div><div><h3>Results</h3><div>Eighty-six patients (mean age of 66.7 ± 7.3 years) were assessed in our study, of whom eleven were catheter-dependent. The mean preoperative prostate size was (71.4 ± 15.6 cc). A statistically significant improvement was recorded in all voiding parameters at 3 months, including maximum urinary flow rate, International Prostate Symptom Score, quality of life, and post-void residual (<em>P</em> &lt; 0.001), with sustained benefits at 48 months. Adverse events were mostly Clavien grade 1 and 2, including urinary retention (11.6%). Two patients (2.3%) required endoscopic intervention for clot retention, representing grade 3B complications. No sexually related adverse events were recorded in our study. The retreatment rate increased at 48 months, with 41.8% requiring medical therapy and 19.7% undergoing surgical retreatment.</div></div><div><h3>Conclusion</h3><div>Rezūm therapy demonstrates both safety and efficacy in managing benign prostatic hyperplasia-related lower urinary tract symptoms, offering maximum benefit within the first 2 years after treatment. Patient selection and counseling regarding the potential need for future medical or surgical retreatment are recommended to optimize long-term outcomes and patients’ satisfaction.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 1","pages":"Pages 97-103"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147552249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice patterns of Urological Society of Australia and New Zealand urologists regarding pelvic lymph node dissection in prostate cancer surgery","authors":"Patrick-Julien Treacy ,&nbsp;Ruban Thanigasalam ,&nbsp;Jacob Bird ,&nbsp;Kate Alexander ,&nbsp;Nicholas Hirst ,&nbsp;Thomas Li ,&nbsp;Amandeep Virk ,&nbsp;Sascha Karunaratne ,&nbsp;Daniel Steffens ,&nbsp;Juliette Cotte ,&nbsp;Scott Leslie","doi":"10.1016/j.prnil.2025.09.003","DOIUrl":"10.1016/j.prnil.2025.09.003","url":null,"abstract":"<div><h3>Background</h3><div>The objective of this study was to investigate the current approach of urologists within the Urological Society of Australia and New Zealand (USANZ) regarding the clinical criteria and anatomical templates for performing pelvic lymph node dissection (PLND) for prostate cancer (PCa) patients in the era of magnetic resonance imaging (MRI) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography imaging technologies.</div></div><div><h3>Materials and methods</h3><div>An online cross-sectional survey was distributed to all USANZ members. Participants were questioned about their expertise, surgical volume, clinical focus of practice, preoperative imaging approach, indications and anatomical description of PLND, and surgical approach.</div></div><div><h3>Results</h3><div>Of the 611 members invited, 113 (18%) responded to the survey and were included. Most urologists were working in private practice (49%) and completed a uro-oncology fellowship (73%). Fifty-five percent had finished their training over 10 years ago. Forty-two percent had performed more than 50 procedures a year, and 60% of them were done robotically. Ninety-seven percent of urologists routinely performed a preoperative magnetic resonance imaging and 18% performed a systematic PSMA-PET scan. When performing more than one technique, the indication and extent of the PLND was dependent on the technique for 9% of urologists. The anatomical extent of the routine PLND was mainly obturator fossa and external iliac (98% and 68%, respectively). Most urologists performed bilateral PLND on unfavorable intermediate-/high-risk PCa patients (75%).</div></div><div><h3>Conclusions</h3><div>The findings of this survey offer a valuable understanding into the current practices of USANZ urologists regarding PLND in PCa surgery, which highlights the absence of consistency in determining the indication and extent of this procedure. PSMA-PET scans have an impact on the urologist’s decision-making practices and therefore warrant further examination.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"14 1","pages":"Pages 29-34"},"PeriodicalIF":2.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147552161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}